Hepatic Arterial Infusion of Mitomycin C with Degradable Starch Microspheres for Unresectable Intrahepatic Cholangiocarcinoma

Shitara, Kohei; Ikami, I; Munakata, Masaki; Muto, Osamu; Sakata, Yuh

doi:10.1016/j.clon.2007.12.007

Cited by 37 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 To overcome these side effects of MMC, and to obtain higher efficacy of the treatment, many attempts have been made to incorporate and deliver the drug in different delivery systems. These attempts include intratumoral injection of MMC-dextran conjugates, 12 starch microspheres, 13,14 and incorporation of MMC in polylactic acid nanoparticles. 15 Microemulsions (M) are self-aggregated thermodynamically stabile systems in which oil and water are homogenously dispersed in each other with the help of a suitable surfactant or surfactant/cosurfactant blend.…”

Section: Introductionmentioning

confidence: 99%

Determination ofIn VivoBehavior of Mitomycin C-Loaded O/W Soybean Oil Microemulsion and Mitomycin C Solution Via Gamma Camera Imaging

Kotmakçı

Kantarcı

Aşıkoğlu

et al. 2013

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

In this study, a microemulsion system was evaluated for delivery of mitomycin C (MMC). To track the distribution of the formulated drug after intravenous administration, radiochemical labeling and gamma scintigraphy imaging were used. The aim was to evaluate a microemulsion system for intravenous delivery of MMC and to compare its in vivo behavior with that of the MMC solution. For microemulsion formulation, soybean oil was used as the oil phase. Lecithin and Tween 80 were surfactants and ethanol was the cosurfactant. To understand the whole body localization of MMC-loaded microemulsion, MMC was labeled with radioactive technetium and gamma scintigraphy was applied for visualization of drug distribution. Radioactivity in the bladder 30 minutes after injection of the MMC solution was observed, according to static gamma camera images. This shows that urinary excretion of the latter starts very soon. On the other hand, no radioactivity appeared in the urinary bladder during the 90 minutes following the administration of MMC-loaded microemulsion. The unabated radioactivity in the liver during the experiment shows that the localization of microemulsion formulation in the liver is stable. In the light of the foregoing, it is suggested that this microemulsion formulation may be an appropriate carrier system for anticancer agents by intravenous delivery in hepatic cancer chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Determination ofIn VivoBehavior of Mitomycin C-Loaded O/W Soybean Oil Microemulsion and Mitomycin C Solution Via Gamma Camera Imaging

Kotmakçı

Kantarcı

Aşıkoğlu

et al. 2013

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Starch, an abundant, non-toxic, biodegradable, edible, and relatively inexpensive material has been used widely in the entrapment of food ingredients (Jafari et al, 2008;Loksuwan, 2007;Bayram et al, 2005;Krishnan et al, 2005) and drugs (Shitara et al, 2008;Stertman et al, 2006;Illum et al, 2001). Research pertaining to the preparation of starch-based microparticles for food application has mainly been focused on using spray drying method.…”

Section: Introductionmentioning

confidence: 99%

Fabrication of starch-based microparticles by an emulsification-crosslinking method

Wang

Liu

et al. 2009

Journal of Food Engineering

View full text Add to dashboard Cite

“…Partial response, stable disease, and progressive disease rates were 7.7 and 81.4%, 41.2 and 100% (only hepatocellular carcinoma, 61.1% for ICC), as well as 0 and 30.8%, respectively [23,24,25,28,29]. It is noteworthy that three original series on HAI for advanced ICC were not mentioned in the above-cited review [30,31,32]. In two of the studies with a total of 23 patients, repetitive HAI was performed with different regimens including gemcitabine, oxaliplatin, 5-FU, adriamycin, epirubicin, mitomycin C, and/or cisplatin [30,32].…”

Section: Locoregional Therapymentioning

confidence: 99%

“…The tumor control rates were 91.0 and 82.0%, and the overall survival was 9.1 months (median) and 26.0 months (mean). In the third study, Shitara et al [31] noted the use of HAI with mitomycin C in combination with degradable starch microspheres. After a total of 204 cycles in 20 patients (median maximum tumor diameter: 7.8 cm, median tumor number: 3, extrahepatic disease rate: 85.0%), the tumor response rate was 50.0% and the median overall survival 14.1 months.…”

Section: Locoregional Therapymentioning

confidence: 99%

Locoregional Therapies of Cholangiocarcinoma

2016

View full text Add to dashboard Cite

Background: Cholangiocarcinoma (CC) is the second most primary liver malignancy with increasing incidence in Western countries. Currently, surgical R0 resection is regarded as the only potentially curative treatment. The results of systemic chemotherapy and best supportive care (BSC) in patients with metastatic disease are often disappointing in regard to toxicity, oncologic efficacy, and overall survival. In current practice, the use of different locoregional therapies is increasingly more accepted. Methods: A review of the literature on locoregional therapies for intrahepatic cholangiocarcinoma (ICC) was undertaken. Results: There are no prospective randomized controlled trials. For localized ICC, either primary or recurrent, radiofrequency ablation (RFA) is by far the most commonly used thermal ablation modality. Thereby, a systematic review and meta-analysis reports major complication in 3.8% as well as 1-, 3-, and 5-year overall survival rates of 82, 47, and 24%, respectively. In selected patients (e.g. with a tumor diameter of ≤3 cm), oncologic efficacy and survival after RFA are comparable with surgical resection. For diffuse ICC, different transarterial therapies, either chemotherapy-based (hepatic artery infusion (HAI), transarterial chemoembolization (TACE)) or radiotherapy-based (transarterial radioembolization (TARE)), show extremely promising results. With regard to controlled trials (transarterial therapy versus systemic chemotherapy, BSC or no treatment), tumor control is virtually always better for transarterial therapies and very often accompanied by a dramatic survival benefit and improvement of quality of life. Of note, the latter is the case not only for patients without extrahepatic metastatic disease but also for those with liver-dominant extrahepatic metastatic disease. There are other locoregional therapies such as microwave ablation, irreversible electroporation, and chemosaturation; however, the current data support their use only in controlled trials or as last-line therapy. Conclusion: Dedicated locoregional therapies are commonly used for primary and recurrent ICC as well as liver-only and liver-dominant extrahepatic metastatic disease. Currently, the best evidence and most promising results are available for RFA, HAI, TACE, and TARE. In cohort studies, the overall survival rates are similar to those obtained with surgery or systemic therapies. Prospective randomized controlled trials are warranted to compare safety and efficacy between different surgical, interventional, and systemic therapies, as well as their combinations.

show abstract

Hepatic Arterial Infusion of Mitomycin C with Degradable Starch Microspheres for Unresectable Intrahepatic Cholangiocarcinoma

Cited by 37 publications

References 20 publications

Determination ofIn VivoBehavior of Mitomycin C-Loaded O/W Soybean Oil Microemulsion and Mitomycin C Solution Via Gamma Camera Imaging

Determination ofIn VivoBehavior of Mitomycin C-Loaded O/W Soybean Oil Microemulsion and Mitomycin C Solution Via Gamma Camera Imaging

Fabrication of starch-based microparticles by an emulsification-crosslinking method

Locoregional Therapies of Cholangiocarcinoma

Contact Info

Product

Resources

About